PMID- 29703252
OWN - NLM
STAT- MEDLINE
DCOM- 20181127
LR  - 20181127
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Apr 27
TI  - Investigation of the SLC22A23 gene in laryngeal squamous cell carcinoma.
PG  - 477
LID - 10.1186/s12885-018-4381-y [doi]
LID - 477
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is the second most common 
      cancer of the head and neck. In order to identify differentially expressed genes 
      which may have a role in LSCC carcinogenesis, we performed GeneFishing Assay. One 
      of the differentially expressed genes was the SLC22A23 (solute carrier family 22, 
      member 23) gene. SLC22A23 belongs to a family of organic ion transporters that 
      are responsible for the absorption or excretion of many drugs, xenobiotics and 
      endogenous compounds in a variety of tissues. SLC22A23 is expressed in a various 
      tissues but no substrates or functions have been identified for it. Although the 
      exact function is unknown, single nucleotide polymorphisms (SNPs) which are 
      located in SLC22A23 gene were associated with inflammatory bowel disease (IBD), 
      endometriosis-related infertility and the clearance of antipsychotic drugs. On 
      the other hand SLC22A23 is identified as a prognostic gene to predict the 
      recurrence of triple-negative breast cancer. METHODS: To understand the role of 
      the SLC22A23 gene in laryngeal carcinogenesis, we investigated its mRNA 
      expression level in laryngeal tumor tissue and adjacent non-cancerous tissue 
      samples obtained from 83 patients by quantitative real-time PCR. To understand 
      the association between SNPs in SLC22A23 and LSCC, selected genetic variations 
      (rs4959235, rs6923667, rs9503518) were genotyped. RESULTS: We found that SLC22A23 
      expression was increased in 46 of 83 tumor tissues (55.4%) and was decreased in 
      30 of 83 (36.1%) tumor tissues compared to normal tissues. 77.2% of patients were 
      homozygote for genotype rs9503518-AA and they most frequently had histological 
      grade 2 and 3 tumors. We also found that rs9503518-AA genotype is associated with 
      increased SLC22A23 expression. CONCLUSIONS: Our results indicate that SLC22A23 
      may play a role in the development of laryngeal cancer.
FAU - Ekizoglu, Seda
AU  - Ekizoglu S
AD  - Cerrahpasa Medical Faculty, Department of Medical Biology, Istanbul University, 
      Kocamustafapasa, 34098, Istanbul, Turkey.
FAU - Seven, Didem
AU  - Seven D
AD  - Cerrahpasa Medical Faculty, Department of Medical Biology, Istanbul University, 
      Kocamustafapasa, 34098, Istanbul, Turkey.
FAU - Ulutin, Turgut
AU  - Ulutin T
AD  - Cerrahpasa Medical Faculty, Department of Medical Biology, Istanbul University, 
      Kocamustafapasa, 34098, Istanbul, Turkey.
FAU - Guliyev, Jalal
AU  - Guliyev J
AD  - Cerrahpasa Medical Faculty, Department of Otorhinolaryngology, Istanbul 
      University, Istanbul, Turkey.
FAU - Buyru, Nur
AU  - Buyru N
AD  - Cerrahpasa Medical Faculty, Department of Medical Biology, Istanbul University, 
      Kocamustafapasa, 34098, Istanbul, Turkey. nbuyru@yahoo.com.
LA  - eng
GR  - 49005/Bilimsel Arastirma Projeleri Birimi, Istanbul Universitesi/International
GR  - 24305/Bilimsel Arastirma Projeleri Birimi, Istanbul Universitesi/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180427
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Organic Anion Transporters)
RN  - 0 (SLC22A23 protein, human)
SB  - IM
MH  - Aged
MH  - Alleles
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Female
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Organic Anion Transporters/*genetics
MH  - Polymorphism, Single Nucleotide
MH  - Reproducibility of Results
PMC - PMC5921549
OTO - NOTNLM
OT  - Expression
OT  - GeneFishing
OT  - Genotyping
OT  - Laryngeal cancer
OT  - SLC22A23
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The study was approved by the 
      Cerrahpasa Medical Faculty Ethics Committee (Approval number: 
      83045809/604.01/02-235,918), and has been performed in accordance with the 
      ethical standarts laid down in the 2013 Declaration of Helsinki. Signed informed 
      consent was obtained from all patients included in the study. COMPETING 
      INTERESTS: The authors declare that they have no competing interest. PUBLISHER'S 
      NOTE: Springer Nature remains neutral with regard to jurisdictional claims in 
      published maps and institutional affiliations.
EDAT- 2018/04/29 06:00
MHDA- 2018/11/28 06:00
PMCR- 2018/04/27
CRDT- 2018/04/29 06:00
PHST- 2017/03/07 00:00 [received]
PHST- 2018/04/17 00:00 [accepted]
PHST- 2018/04/29 06:00 [entrez]
PHST- 2018/04/29 06:00 [pubmed]
PHST- 2018/11/28 06:00 [medline]
PHST- 2018/04/27 00:00 [pmc-release]
AID - 10.1186/s12885-018-4381-y [pii]
AID - 4381 [pii]
AID - 10.1186/s12885-018-4381-y [doi]
PST - epublish
SO  - BMC Cancer. 2018 Apr 27;18(1):477. doi: 10.1186/s12885-018-4381-y.